By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Wyeth v. Apotex Inc. et al.
1:08-cv-22308; filed August 18, 2008 in the Southern District of Florida
Infringement of U.S. Patent Nos. 6,274,171 ("Extended release formulation of venlafaxine hydrochloride," issued August 14, 2001), 6,403,120 (same title, issued June 11, 2002), and 6,419,958 (same title, issued July 16, 2002) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Wyeth's EFFEXOR XR® (venlafaxine hydrochloride, extended release, used to treat depression). View the complaint here.
Purdue Pharma Products LP et al. v. Impax Laboratories Inc.
1:08-cv-00519; filed August 15, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. 6,254,887 ("Controlled Release Tramadol," issued July 3, 2001) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of plaintiffs' Ultram® ER (tramadol hydrochloride, used to treat moderate to moderately severe chronic pain). View the complaint here. [NB: as we reported here, essentially the same complaint was previously filed, however it was voluntarily dismissed without prejudice on August 18, 2008.]
Hoffman-La Roche, Inc. v. Cobalt Pharmaceutiacls Inc. et al.
2:08-cv-04054; filed August 12, 2008 in the District Court of New Jersey
Hoffmann-La Roche, Inc. v. Gate Pharmaceuticals et al.
2:08-cv-04058; filed August 12, 2008 in the District Court of New Jersey
Hoffmann-La Roche, Inc. v. Mutual Pharmaceutical Company, Inc.
2:08-cv-04060; filed August 12, 2008 in the District Court of New Jersey
Hoffmann-La Roche, Inc. v. Genpharm Inc. et al.
2:08-cv-04052; filed August 12, 2008 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 7,410,957 ("Method of Treatment Using Bisphosphonic Acid," issued August 12, 2008) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Roche's Boniva® (150 mg once-monthly tablets) (ibandronate sodium, used to treat post-menopausal osteoporosis). View the Cobalt Pharmaceuticals complaint here.
Comments